AU8109794A - 7h-imidazo(1,2-a)pyrazine-8-one nmda receptor antagonists - Google Patents

7h-imidazo(1,2-a)pyrazine-8-one nmda receptor antagonists

Info

Publication number
AU8109794A
AU8109794A AU81097/94A AU8109794A AU8109794A AU 8109794 A AU8109794 A AU 8109794A AU 81097/94 A AU81097/94 A AU 81097/94A AU 8109794 A AU8109794 A AU 8109794A AU 8109794 A AU8109794 A AU 8109794A
Authority
AU
Australia
Prior art keywords
imidazo
pyrazine
receptor antagonists
nmda receptor
nmda
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU81097/94A
Inventor
Jean-Claude Aloup
Francois Audiau
Dominique Damour
Arielle Genevois-Borella
Patrick Jimonet
Serge Mignani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Publication of AU8109794A publication Critical patent/AU8109794A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU81097/94A 1993-11-05 1994-11-02 7h-imidazo(1,2-a)pyrazine-8-one nmda receptor antagonists Abandoned AU8109794A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9313164 1993-11-05
FR9313164A FR2711993B1 (en) 1993-11-05 1993-11-05 Drugs containing 7H-imidazol [1,2-a] pyrazine-8-one derivatives, new compounds and their preparation.
PCT/FR1994/001268 WO1995012594A1 (en) 1993-11-05 1994-11-02 7H-IMIDAZO(1,2-a)PYRAZINE-8-ONE NMDA RECEPTOR ANTAGONISTS

Publications (1)

Publication Number Publication Date
AU8109794A true AU8109794A (en) 1995-05-23

Family

ID=9452533

Family Applications (1)

Application Number Title Priority Date Filing Date
AU81097/94A Abandoned AU8109794A (en) 1993-11-05 1994-11-02 7h-imidazo(1,2-a)pyrazine-8-one nmda receptor antagonists

Country Status (7)

Country Link
EP (1) EP0726900A1 (en)
JP (1) JPH09504539A (en)
AU (1) AU8109794A (en)
FR (1) FR2711993B1 (en)
IL (1) IL111526A0 (en)
WO (1) WO1995012594A1 (en)
ZA (1) ZA948592B (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040155A1 (en) * 1995-06-07 1996-12-19 The Johns Hopkins University Use of specific acpa derivative (npc-17742) for the treatment of ischemia
BR0309398A (en) 2002-04-19 2005-02-01 Cellular Genomics Inc A compound or a salt, hydrate, solvate, crystalline form thereof, diastereomer, pharmaceutically acceptable prodrug, or mixtures thereof, pharmaceutical composition, and methods for treating a condition involved with kinase in a mammal, for treating cancer, and for identifying a kinase.
US7312341B2 (en) 2002-09-09 2007-12-25 Cgi Pharmaceuticals, Inc. 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof
WO2004072081A1 (en) 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
WO2005005429A1 (en) 2003-06-30 2005-01-20 Cellular Genomics, Inc. Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds
WO2005019220A2 (en) 2003-08-11 2005-03-03 Cellular Genomics Inc. Substituted imidazo[1,2-a]pyrazines as modulators of kinase activity
WO2007024294A2 (en) 2005-05-03 2007-03-01 Cgi Pharmaceuticals, Inc. Certain substituted ureas, as modulators of kinase activity
EP1928237A4 (en) 2005-09-02 2011-03-09 Abbott Lab Novel imidazo based heterocycles
JP5379692B2 (en) 2006-11-09 2013-12-25 プロビオドルグ エージー 3-Hydroxy-1,5-dihydro-pyrrol-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcers, cancer and other diseases
EP2091948B1 (en) 2006-11-30 2012-04-18 Probiodrug AG Novel inhibitors of glutaminyl cyclase
JP5930573B2 (en) 2007-03-01 2016-06-15 プロビオドルグ エージー New use of glutaminyl cyclase inhibitors
ES2533484T3 (en) 2007-04-18 2015-04-10 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
US20090221612A1 (en) 2008-02-13 2009-09-03 Mitchell Scott A Certain substituted amides, method of making, and method of use thereof
US8450321B2 (en) 2008-12-08 2013-05-28 Gilead Connecticut, Inc. 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo-[1,2-A]pyrazin-8-amine, or a pharmaceutically acceptable salt thereof, as a SYK inhibitor
DK2716157T3 (en) 2008-12-08 2016-08-15 Gilead Connecticut Inc Imidazopyrazin-Syk inhibitors
CA2745871C (en) 2008-12-08 2018-02-20 Gilead Connecticut, Inc. Imidazopyrazine syk inhibitors
NZ598685A (en) 2009-09-11 2013-05-31 Probiodrug Ag Heterocylcic derivatives as inhibitors of glutaminyl cyclase
ES2586231T3 (en) 2010-03-03 2016-10-13 Probiodrug Ag Glutaminyl cyclase inhibitors
EP2545047B9 (en) 2010-03-10 2015-06-10 Probiodrug AG Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5)
AU2011226689B2 (en) 2010-03-11 2016-09-01 Kronos Bio, Inc. Imidazopyridines Syk inhibitors
EP2560953B1 (en) 2010-04-21 2016-01-06 Probiodrug AG Inhibitors of glutaminyl cyclase
ES2570167T3 (en) 2011-03-16 2016-05-17 Probiodrug Ag Benzimidazole derivatives as glutaminyl cyclase inhibitors
KR20170116203A (en) 2013-07-30 2017-10-18 질레드 코네티컷 인코포레이티드 Formulation of syk inhibitors
US9657023B2 (en) 2013-07-30 2017-05-23 Gilead Connecticut, Inc. Polymorph of Syk inhibitors
SG11201603050TA (en) 2013-12-04 2016-05-30 Gilead Sciences Inc Methods for treating cancers
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
UY35898A (en) 2013-12-23 2015-07-31 Gilead Sciences Inc ? SYK INHIBITING COMPOUNDS AND COMPOSITIONS THAT UNDERSTAND THEM ?.
EP3392244A1 (en) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
ES2760261T3 (en) 2014-02-13 2020-05-13 Incyte Corp Cyclopropylamines as LSD1 inhibitors
MY196877A (en) 2014-02-13 2023-05-08 Incyte Corp Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
US9695180B2 (en) * 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
CA2955180A1 (en) 2014-07-14 2016-01-21 Gilead Sciences, Inc. Combinations comprising entospletinib and a vinca-alkaloid for treating cancers
KR102659373B1 (en) 2015-04-03 2024-04-23 인사이트 홀딩스 코포레이션 Heterocyclic compounds as LSD1 inhibitors
CA2995361A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Salts of an lsd1 inhibitor
CA3021678A1 (en) 2016-04-22 2017-10-26 Incyte Corporation Formulations of an lsd1 inhibitor
CA3073871A1 (en) 2017-08-25 2019-02-28 Gilead Sciences, Inc. Polymorphs of syk inhibitors
ES2812698T3 (en) 2017-09-29 2021-03-18 Probiodrug Ag Glutaminyl cyclase inhibitors
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
AU2020225455A1 (en) 2019-02-22 2021-09-09 Kronos Bio, Inc. Solid forms of condensed pyrazines as Syk inhibitors
WO2023042888A1 (en) 2021-09-15 2023-03-23 国立大学法人 琉球大学 Pharmaceutical composition for treating cognitive decline or for treating overweightness or obesity
WO2023042887A1 (en) 2021-09-15 2023-03-23 国立大学法人 琉球大学 Pharmaceutical composition for use in treating cognitive decline, excess weight, or obesity

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3767793A (en) * 1992-04-03 1993-11-08 Yamanouchi Pharmaceutical Co., Ltd. Fused quinoxalinone derivative and pharmaceutical composition containing the same
FR2696466B1 (en) * 1992-10-02 1994-11-25 Rhone Poulenc Rorer Sa 5H, 10H-imidazo [1,2-a] indeno [1,2-e] pyrazine-4-one derivatives, their preparation and the medicaments containing them.

Also Published As

Publication number Publication date
JPH09504539A (en) 1997-05-06
EP0726900A1 (en) 1996-08-21
FR2711993A1 (en) 1995-05-12
IL111526A0 (en) 1995-01-24
WO1995012594A1 (en) 1995-05-11
FR2711993B1 (en) 1995-12-01
ZA948592B (en) 1995-06-23

Similar Documents

Publication Publication Date Title
AU8109794A (en) 7h-imidazo(1,2-a)pyrazine-8-one nmda receptor antagonists
AU8069291A (en) Substituted 1-h-pyrrolo(2,3-b)pyridine-3-carboxamides
AU2524995A (en) Neurokinine (tachykinine) antagonists
AU7692996A (en) Receptor antagonists
AU660321B2 (en) 1,2-dihydro-2-oxopyridine
AU1441695A (en) Fibrinogen receptor antagonists
AU5276696A (en) Imidazo{1,2-a}pyridine derivatives
AU2734297A (en) Multi-site network database
AU5603094A (en) N,n-diacylpiperazine tachykinin antagonists
AU3665793A (en) Fibrinogen receptor antagonists
AU2042495A (en) Thieno(1,5)benzodiazepine use
AU6781194A (en) 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
HUP9600106A3 (en) 2,9-disubstituted purin-6-one derivatives
AU7447896A (en) Processes for the preparation of octafluoro-{2,2}paracyclophane
AU6856796A (en) Des-arg9-bk antagonists
AP9801212A0 (en) Tetrahydroquin olinesas NMDA antagonists
AU6123196A (en) N-aryl-1,2,4-triazolin-5-ones
AU698867B2 (en) Fused imidazo 1,2-a pyridines
AU1660397A (en) Novel pyrimido(1,2-a)indoles
AU5322994A (en) Fibrinogen receptor antagonists
AU4698889A (en) New substituted pyrido(2,3-d)pyrimidines
AU1373395A (en) Vpr receptor protein
AU641516B2 (en) Back-rest
AU6247490A (en) Nmda antagonists
AU2831392A (en) Substituted 1, 5-pentanediols and processes for the preparation thereof